Mirum Pharmaceuticals, Inc. - 8-K Filing
Mirum Pharmaceuticals announces positive Cohort 2 PROGRESS study results for ATEBRIOZ in pediatric FOP patients aged 6 to <12 years. (Items: 8.01 Other Events)
Tickers: $MIRM
Mirum Pharmaceuticals announces positive Cohort 2 PROGRESS study results for ATEBRIOZ in pediatric FOP patients aged 6 to <12 years. (Items: 8.01 Other Events)
Tickers: $MIRM